Systemic DKK1 neutralization enhances human adipose‐derived stem cell mediated bone repair

• Main Authors: Stefano Negri, Yiyun Wang, Takashi Sono, Qizhi Qin, Ginny Ching‐Yun Hsu, Masnsen Cherief, Jiajia Xu, Seungyong Lee, Robert J. Tower, Victoria Yu, Abhi Piplani, Carolyn A. Meyers, Kristen Broderick, Min Lee, Aaron W. James
• Format: Article
• Language: English
• Published: Wiley 2021-04-01
• Series: Stem Cells Translational Medicine
• Subjects: adipose stem cell; adipose stromal cell; bone healing; bone repair; bone tissue engineering; mesenchymal stem cell
• Online Access: https://doi.org/10.1002/sctm.20-0293
• ISSN: 2157-6564; 2157-6580

Abstract Progenitor cells from adipose tissue are able to induce bone repair; however, inconsistent or unreliable efficacy has been reported across preclinical and clinical studies. Soluble inhibitory factors, such as the secreted Wnt signaling antagonists Dickkopf‐1 (DKK1), are expressed to variable degrees in human adipose‐derived stem cells (ASCs), and may represent a targetable “molecular brake” on ASC mediated bone repair. Here, anti‐DKK1 neutralizing antibodies were observed to increase the osteogenic differentiation of human ASCs in vitro, accompanied by increased canonical Wnt signaling. Human ASCs were next engrafted into a femoral segmental bone defect in NOD‐Scid mice, with animals subsequently treated with systemic anti‐DKK1 or isotype control during the repair process. Human ASCs alone induced significant but modest bone repair. However, systemic anti‐DKK1 induced an increase in human ASC engraftment and survival, an increase in vascular ingrowth, and ultimately improved bone repair outcomes. In summary, anti‐DKK1 can be used as a method to augment cell‐mediated bone regeneration, and could be particularly valuable in the contexts of impaired bone healing such as osteoporotic bone repair.